Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Iowa Methodist Medical Center
565
mi
from 43215
Des Moines, IA
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Iowa Methodist Medical Center
565
mi
from 43215
Des Moines, IA
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Mercy Medical Center - Des Moines
565
mi
from 43215
Des Moines, IA
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Mercy Medical Center - Des Moines
565
mi
from 43215
Des Moines, IA
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Mercy Medical Center - Sioux City
716
mi
from 43215
Sioux City, IA
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Mercy Medical Center - Sioux City
716
mi
from 43215
Sioux City, IA
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
The Memorial Hospital at Easton
380
mi
from 43215
Easton, MD
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
The Memorial Hospital at Easton
380
mi
from 43215
Easton, MD
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Tufts Medical Center
642
mi
from 43215
Boston, MA
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Tufts Medical Center
642
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Baystate Medical Center
563
mi
from 43215
Springfield, MA
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Baystate Medical Center
563
mi
from 43215
Springfield, MA
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Bixby Medical Center
145
mi
from 43215
Adrian, MI
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Bixby Medical Center
145
mi
from 43215
Adrian, MI
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Saint Joseph Mercy Hospital
157
mi
from 43215
Ann Arbor, MI
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Saint Joseph Mercy Hospital
157
mi
from 43215
Ann Arbor, MI
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Hurley Medical Center
213
mi
from 43215
Flint, MI
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Hurley Medical Center
213
mi
from 43215
Flint, MI
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Genesys Hurley Cancer Institute
213
mi
from 43215
Flint, MI
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Genesys Hurley Cancer Institute
213
mi
from 43215
Flint, MI
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Allegiance Health
173
mi
from 43215
Jackson, MI
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Allegiance Health
173
mi
from 43215
Jackson, MI
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Bronson Methodist Hospital
208
mi
from 43215
Kalamazoo, MI
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Bronson Methodist Hospital
208
mi
from 43215
Kalamazoo, MI
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Borgess Medical Center
206
mi
from 43215
Kalamazoo, MI
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Borgess Medical Center
206
mi
from 43215
Kalamazoo, MI
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
West Michigan Cancer Center
210
mi
from 43215
Kalamazoo, MI
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
West Michigan Cancer Center
210
mi
from 43215
Kalamazoo, MI
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Sparrow Hospital
194
mi
from 43215
Lansing, MI
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Sparrow Hospital
194
mi
from 43215
Lansing, MI
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Mercy Memorial Hospital
135
mi
from 43215
Monroe, MI
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Mercy Memorial Hospital
135
mi
from 43215
Monroe, MI
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Marie Yeager Cancer Center
232
mi
from 43215
Saint Joseph, MI
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Marie Yeager Cancer Center
232
mi
from 43215
Saint Joseph, MI
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Saint John Macomb-Oakland Hospital
175
mi
from 43215
Warren, MI
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Saint John Macomb-Oakland Hospital
175
mi
from 43215
Warren, MI
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Essentia Health Saint Joseph's Medical Center
714
mi
from 43215
Brainerd, MN
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Essentia Health Saint Joseph's Medical Center
714
mi
from 43215
Brainerd, MN
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Fairview Ridges Hospital
618
mi
from 43215
Burnsville, MN
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Fairview Ridges Hospital
618
mi
from 43215
Burnsville, MN
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Mercy Hospital
634
mi
from 43215
Coon Rapids, MN
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Mercy Hospital
634
mi
from 43215
Coon Rapids, MN
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Miller-Dwan Hospital
654
mi
from 43215
Duluth, MN
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Miller-Dwan Hospital
654
mi
from 43215
Duluth, MN
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Essentia Health Saint Mary's Medical Center
654
mi
from 43215
Duluth, MN
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Essentia Health Saint Mary's Medical Center
654
mi
from 43215
Duluth, MN
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Fairview Southdale Hospital
625
mi
from 43215
Edina, MN
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Fairview Southdale Hospital
625
mi
from 43215
Edina, MN
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Lake Region Healthcare Corporation-Cancer Care
787
mi
from 43215
Fergus Falls, MN
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Lake Region Healthcare Corporation-Cancer Care
787
mi
from 43215
Fergus Falls, MN
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Unity Hospital
629
mi
from 43215
Fridley, MN
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Unity Hospital
629
mi
from 43215
Fridley, MN
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Hutchinson Area Health Care
671
mi
from 43215
Hutchinson, MN
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Hutchinson Area Health Care
671
mi
from 43215
Hutchinson, MN
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Saint John's Hospital - Healtheast
616
mi
from 43215
Maplewood, MN
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Saint John's Hospital - Healtheast
616
mi
from 43215
Maplewood, MN
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Abbott Northwestern Hospital
629
mi
from 43215
Minneapolis, MN
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Abbott Northwestern Hospital
629
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
New Ulm Medical Center
657
mi
from 43215
New Ulm, MN
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
New Ulm Medical Center
657
mi
from 43215
New Ulm, MN
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
North Memorial Medical Health Center
630
mi
from 43215
Robbinsdale, MN
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
North Memorial Medical Health Center
630
mi
from 43215
Robbinsdale, MN
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Park Nicollet Clinic - Saint Louis Park
627
mi
from 43215
Saint Louis Park, MN
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Park Nicollet Clinic - Saint Louis Park
627
mi
from 43215
Saint Louis Park, MN
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Regions Hospital
617
mi
from 43215
Saint Paul, MN
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Regions Hospital
617
mi
from 43215
Saint Paul, MN
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
United Hospital
618
mi
from 43215
Saint Paul, MN
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
United Hospital
618
mi
from 43215
Saint Paul, MN
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Saint Francis Regional Medical Center
630
mi
from 43215
Shakopee, MN
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Saint Francis Regional Medical Center
630
mi
from 43215
Shakopee, MN
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Lakeview Hospital
609
mi
from 43215
Stillwater, MN
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Lakeview Hospital
609
mi
from 43215
Stillwater, MN
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Ridgeview Medical Center
643
mi
from 43215
Waconia, MN
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Ridgeview Medical Center
643
mi
from 43215
Waconia, MN
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Rice Memorial Hospital
707
mi
from 43215
Willmar, MN
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Rice Memorial Hospital
707
mi
from 43215
Willmar, MN
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Saint Francis Medical Center
397
mi
from 43215
Cape Girardeau, MO
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Saint Francis Medical Center
397
mi
from 43215
Cape Girardeau, MO
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Nevada Cancer Research Foundation CCOP
1756
mi
from 43215
Las Vegas, NV
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Nevada Cancer Research Foundation CCOP
1756
mi
from 43215
Las Vegas, NV
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Veterans Adminstration New Jersey Health Care System
467
mi
from 43215
East Orange, NJ
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Veterans Adminstration New Jersey Health Care System
467
mi
from 43215
East Orange, NJ
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Hematology Oncology Associates, PC
1331
mi
from 43215
Albuquerque, NM
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Hematology Oncology Associates, PC
1331
mi
from 43215
Albuquerque, NM
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
University of New Mexico Cancer Center
1332
mi
from 43215
Albuquerque, NM
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
University of New Mexico Cancer Center
1332
mi
from 43215
Albuquerque, NM
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Memorial Medical Center - Las Cruces
1421
mi
from 43215
Las Cruces, NM
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Memorial Medical Center - Las Cruces
1421
mi
from 43215
Las Cruces, NM
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Toledo Clinic Cancer Centers-Bowling Green
mi
from 43215
Bowling Green, OH
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Toledo Clinic Cancer Centers-Bowling Green
mi
from 43215
Bowling Green, OH
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
MetroHealth Med Ctr
127
mi
from 43215
Cleveland, OH
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
MetroHealth Med Ctr
127
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
North Coast Cancer Care - Clyde
92
mi
from 43215
Clyde, OH
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
North Coast Cancer Care - Clyde
92
mi
from 43215
Clyde, OH
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Hematology Oncology Center Incorporated
108
mi
from 43215
Elyria, OH
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Hematology Oncology Center Incorporated
108
mi
from 43215
Elyria, OH
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Lima Memorial Hospital
76
mi
from 43215
Lima, OH
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Lima Memorial Hospital
76
mi
from 43215
Lima, OH
Click here to add this to my saved trials
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated:  12/31/1969
Saint Luke's Hospital
115
mi
from 43215
Maumee, OH
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
Status: Enrolling
Updated: 12/31/1969
Saint Luke's Hospital
115
mi
from 43215
Maumee, OH
Click here to add this to my saved trials